Document:

EMPLOYMENT AGREEMENT BETWEEN

ZANDER THERAPEUTICS, INC.

AND

Todd S. Caven

 

THIS EMPLOYMENT AGREEMENT (the "Agreement") dated
as of August 21, 2017 is entered into between Zanderr Therapeutics, Inc., a Nevada corporation, (the "Company") and
Todd S. Caven ("Employee").

 

WITNESSETH:

WHEREAS, Employee
and the Company desire to enter into an agreement providing for the employment by the Company of Employee upon the terms
provided herein.

REPRESENTATIONS AND WARRANTIES

A) Company hereby represents and warrants to Employee
as follows;

(i) Corporate Existence of Company.
Company:

(a) is a corporation duly formed, validly existing
and in good standing under the laws of the State of Nevada and

(b) has all requisite power and authority, and has
all governmental licenses, authorizations, consents and approvals necessary to execute and deliver this Agreement and to consummate
the transactions contemplated by this Agreement.

 

(ii) No Conflicts. None of the
execution, delivery and performance of this Agreement by Company, or the consummation or the transactions
contemplated hereby and thereby

 

(a) constitutes or will constitute a violation of the
organizational documents of Company,

(b) constitutes or will constitute
a breach or violation of, or a default (or an event which, with notice or lapse of time or
both, would constitute such a default) under, any indenture, mortgage, deed of Company, loan agreement, lease or
other agreement or instrument to which Company is a party or by which Company or any of its
properties may be bound,

(c) violates or will violate
any statute, law or regulation or any order, judgment, decree or injunction of any court or Governmental
Authority directed to Company or any of its properties in a proceeding to which its property
is or was a party.

 

(B) Employee hereby represents and warrant to Company
as follows:

(i) No Conflicts. None of the execution, delivery
and performance of this Agreement by Employee, or the consummation of the transactions contemplated hereby and thereby

(a) constitutes or will constitute a breach or violation
of, or a default (or an event which, with notice or lapse of time or both, would constitute such a default) under, any indenture,
mortgage, deed of Trust, loan agreement, lease or other agreement or instrument to which Employee is a party or by which Employee
or any of its properties may be bound,

(b) violates or will violate any statute, law or
regulation or any order, judgment, decree or injunction of any court or Governmental Authority directed to Employee or any of their
properties in a proceeding to which its property is or was a party.

AGREEMENT:

	 	1	 

    	 

    	 

    

 

NOW, THEREFORE, in consideration of the foregoing and
the mutual promises and agreements set forth herein, the parties hereto, intending to be legally bound, hereby agree as follows:

1. Employment. During the Employment Period (as defined
in Section 2), the Company hereby employs Employee and Employee hereby accepts employment.

2. Term. The Term of this Agreement shall commence on
August 15, 2017 and shall expire on August 14, 2019 unless sooner terminated in accordance with the provisions of Section 6 hereof;
provided, however, that the term of this Agreement may be extended by mutual agreement. The period from the commencement of the
term of this Agreement to the date of its expiration or sooner termination shall be considered to be the “Employment Period"
hereunder. AT THE END OF THE EMPLOYMENT PERIOD, THIS AGREEMENT MAY BE EXTENDED FOR AN ADDITIONAL YEAR BY WRITTEN MUTUAL CONSENT
OF THE PARTIES HERETO.

3. Duties. Employee shall be granted the title of President
and Chief Scientific Officer of the Company subject to the authority of the Company's Chief Executive Officer (the “CEO”).
Employee shall perform such duties commensurate with his office and as directed the CEO such duties to include, but not be limited
to:

 

See Schedule 1.

 

During the Employment Period, Employee shall perform
his duties hereunder in a diligent manner, subject to the provisions of Schedule 1 of this Agreement; devoting such amount of his
business time, attention and efforts to the affairs of the Company within the scope of his employment as is necessary for the proper
rendition of such service and shall use his best efforts to promote the best interests of the Company. Employee's services shall
be rendered when and as required by the Board and in accordance with his instructions, direction and control.

It is agreed that Employee will only devote such time
as to effectively conduct duties and responsibilities associated with this position pursuant to this Agreement.

4. Compensation Salary. During
the Employment Period, Company shall pay Employee salary at the rate of:

 

	 	(i)	During that period commencing August 15, 2017 and ending on the sooner of (a) the expiration of the Employment Period or (b) the last day of any month during the Employment period in which the Company shall have sold equity or debt securities generating net cash proceeds to the Company of Two Million Dollars ($2,000,000) or more (“Capital Raise”) Employee shall receive from the Company 10,000 shares of the Company's Series M Preferred stock per month as compensation for Employee’s services pursuant to this Agreement .

 

	 	(ii)	During the period commencing the first day subsequent to the end of that month in which the successful completion by the Company of the Capital Raise shall have occurred and ending upon the expiration of the Employment Period, Company shall pay Employee salary at the rate of $16,667 per month prorated for any partial employment month ("Salary"). Salary shall be paid on a monthly basis (“Payday”). In the event that Payday falls on a Saturday, Sunday or holiday, Salary shall be paid on the next business day. Salary may be paid, at the Company’s sole discretion, either in:

 

(a)        
cash, or

(b)        
10,000 shares of the Company’s Series M Preferred stock (“Stock Payment”)

(c)       Registered
shares of the Company's common stock (number of shares to be issued to employee =salary/previous day’s closing price prior
to submitting issuance documents to transfer agent)

 

Employee acknowledges that any Stock
Payments issued pursuant to this Agreement that are not registered pursuant to the Securities Act of 1933 shall constitute
“restricted securities” as that term is defined in Rule 144 promulgated under the Securities Act of 1933, and shall
contain the following restrictive legend:

 

THESE SECURITIES HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED, SOLD,
ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN

	 	2	 

    	 

    	 

    

 

EFFECTIVE REGISTRATION STATEMENT UNDER
THE ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION UNDER THE ACT OR SUCH LAWS
AND, IF REQUESTED BY THE COMPANY, UPON DELIVERY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT THE PROPOSED
TRANSFER IS EXEMPT FROM THE ACT OR SUCH LAWS.

 

The Company may register any Stock Payment
pursuant to the Securities Act of 1933, but is not obligated to do so pursuant to this Agreement.

 

5. Benefits.

a. During the Employment Period, Employee shall be entitled
to participation in any profit sharing plan, retirement plan, group life insurance plan or other insurance plan, medical expense
plan, medical and dental insurance and other benefit arrangements maintained by the Company for its employees generally and, if
applicable, their family members. In addition, Employee shall be entitled to 15 days paid vacation (“Vacation”) subject
to having given fourteen days prior notice to the Company of Employee’s intent to Vacation.

b.        Stock Compensation. 
Employee acknowledges he has received 500,000 Series M Preferred shares that are fully vested and considered compensation in full
for service prior to the execution of this agreement .Employee acknowledges that any Series M Shares  issued prior to or pursuant
to this Agreement will not be  registered pursuant to the Securities Act of 1933 , shall constitute “restricted securities”
as that term is defined in Rule 144 promulgated under the Securities Act of 1933 and shall contain the following restrictive legend:

THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED, SOLD, ASSIGNED,
PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND APPLICABLE
STATE SECURITIES LAWS OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION UNDER THE ACT OR SUCH LAWS AND, IF REQUESTED BY THE
COMPANY, UPON DELIVERY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT THE PROPOSED TRANSFER IS EXEMPT FROM
THE ACT OR SUCH LAWS.

d.       Milestone
Shares. Employee shall receive another an aggregate of 10,000,000 newly issued Series M Preferred shares of the Company upon achievement
of milestones (“Milestone Shares”).  The shares shall be subject to a vesting schedule (See Schedule 2)

 

 

6. Termination.

a. Employee's employment hereunder
shall terminate upon the earlier of:

(i) the expiration of the Employment Period,

(ii) the death of Employee,

(iii) the expiration of a continuous period of thirty
(30) calendar days during which Employee is unable to perform his material duties due to physical or mental incapacity,

(iv) termination by the Company due to “just
cause,”

(v) termination by Employee due to a material breach
of this Agreement by the Company. The exercise of the right of the Company or Employee to terminate this Agreement pursuant to
clauses

	 	3	 

    	 

    	 

    

 

(iv) or (v) hereof, as the case may be, shall not
abrogate the rights and remedies of the terminating party in respect of the breach giving rise to such termination.

b. "Just cause" hereunder
shall be defined and limited to mean:

(i) Employee's failure or refusal, as determined
by the CEO in his sole discretion, to perform specific directives of the CEO which are consistent with the scope and nature of
Employee's duties and responsibilities as set forth herein (including the duties described in Section 3), which failure or refusal
continues after notice thereof and a reasonable time to cure; such reasonable time to be determined by the CEO.

(ii) Employee's conviction for a felony or any crime
involving moral turpitude, fraud, or misrepresentation, or the presentation of proof satisfactory to the CEO in the exercise of
his reasonable judgment of Employee's misappropriation or embezzlement of funds or assets from the Company;

(iii) any intentional act having the purpose and
effect of injuring the reputation, business or business relationships of the Company in any material respect; and

(iv) any breach by Employee of any material provision
of this Agreement, including, without limitation, the restrictive covenants contained in Section 7 hereof.

c. In the event of any dispute regarding the existence
of Employee's incapacity hereunder, the matter wil1 be resolved by the determination of a physician qualified to practice medicine
in California selected by the CEO. For this purpose, Employee will submit to appropriate medical examinations.

d. If Employee's employment hereunder is terminated
pursuant to Section 6, the Company shall have no further obligations or liabilities hereunder.

7. Restrictive Covenant.

a. Non-disclosure. Employee has, and during the
Employment Period will have, access to confidential information and trade secrets of the Company and its subsidiaries (the "Confidential
Information") that may include, among other things:

(i) Financial information

(ii) Supply and services information

(iii) Marketing information

(iv) Personnel information

(v) Customer information

(vi) Product information

(vii) The Company’s procedures, systems, policies
and processes of operation.

 

Employee shall at all times during his employment
by the Company and thereafter hold in strictest confidence any and all Confidential Information that may have come or may come
into Employee's possession or within Employee's knowledge. Employee agrees that neither he nor any person or entity, directly or
indirectly, controlled by or under common control with the Employee (an "Affiliate")will for any reason, except in the
course of performing his duties hereunder, for himself or any other person, use or disclose to anyone, exclusive of Company employees,
agents, representatives, or independent consultants to

	 	4	 

    	 

    	 

    

 

the Company or any of its subsidiaries or Affiliates
of the Company, any Confidential Information; provided, however, that Employee may disclose Confidential Information which (i)
has become generally available to the public other than as a result of a breach of this Agreement by Employee or (ii) Employee
is compelled to disclose pursuant to subpoena or an order by a court competent jurisdiction; provided that, if Employee is so required
to disclose any Confidential Information pursuant to the foregoing clause (ii), Employee shall provide advance written notice to
the Company, to the extent possible, to allow the Company to seek an appropriate protective order therefore (iii) Potential advisors,
employees, or investors of the Company where there is a reasonable expectation of confidentiality. All Confidential Information
shall remain the Company's property and shall be returned (or, at the Company's option, destroyed) upon the Company's written request.

b. Non-Solicitation of Employees. Employee agrees
that from the date hereof and continuing for a period of three years following the termination of this Agreement for whatever reason
(the "Non-Compete Period"), neither Employee nor any Affiliate of Employee will solicit or hire for employment any officer,
director or employee of the Company who was employed by the Company at any time within twelve months prior to the act of solicitation.

c. Non-Competition. Employee agrees that, other
than with the approval of the CEO, which approval shall not be unreasonably withheld, during the Employment Period, neither Employee
nor any Affiliate of Employee will, directly or indirectly, become a shareholder, director, officer, agent, partner or employee
of, or otherwise hold any ownership interest in, any person, firm or entity engaged in any Competitive Business (as defined below),
engage as a sole proprietor in any Competitive Business, act as a consultant to or assist any of the foregoing or otherwise engage
or participate in any Competitive Business; provided, however, that the foregoing shall not prohibit the ownership by Employee
of less than ten percent (10%) of the outstanding shares of the stock of any corporation engaged in any Competitive Business, which
shares are regularly traded on a national securities exchange or in any over-the-counter market. For the purpose hereof, "Competitive
Business" means the ownership, operation, development, marketing of the services related to, or management of cellular therapeutics
within the United States.

d. Consideration, Relief, Reformation; Severability.
The Company has specifically bargained for the covenants set forth in this Section 6 in consideration for the compensation, experience,
and information that Employee will gain or receive in connection with his employment by the Company. Employee agrees that the covenants
set forth herein will not preclude Employee from engaging in any lawful profession, trade or business or from being gainfully employed
necessary to provide Employee, his family members and dependents a standard of living to which he and they have been accustomed
and may expect. Employee acknowledges and agrees that the restrictive covenants in this Section 6 have been specifically negotiated,
are reasonable in all respects, including, without limitation, their geographic scope and duration, and may be enforced by specific
performance or otherwise. Employee shall not raise any issue of reasonableness as a defense in any proceeding to enforce any of
such covenants. Notwithstanding the foregoing, in the event that a covenant included in this Agreement shall be deemed by any court
to be unreasonably broad in any respect, it shall be modified or limited in its geographic scope, duration or otherwise to the
extent necessary to make it reasonable while preserving its restrictive nature to the maximum degree possible and shall be enforced
accordingly; provided however, that if, notwithstanding the foregoing, a court of competent jurisdiction shall hold any of the
covenants contained in Sections 7 (a), (b) or (c) to be unenforceable (as so modified), then the unenforceable covenant shall be
deemed eliminated from the provisions of this Agreement for the purpose of those proceedings to the extent necessary to permit
the remaining covenants to be enforced so that the validity, legality or enforceability of the remaining provisions of this Agreement
shall not be affected thereby.

8. Developments.

Employee hereby assigns to the Company his
entire right, title and interest in all know how, discoveries and improvements, customer lists, trade secrets
and ideas, writings and copyrightable material, which may be conceived by Employee or developed or
acquired by him during the term of this Agreement, which may pertain directly to the Company's business and
were developed with Company resources. Employee agrees to promptly and

	 	5	 

    	 

    	 

    

 

fully disclose in writing all such
developments. Employee will, upon the Company's request, execute, acknowledge and deliver to the
Company all instruments and do all other acts which are necessary or desirable to entitle the Company
to all rights in the foregoing and enable the Company to file and prosecute applications for, and to acquire, maintain and
enforce all letters, trademark registrations or copyrights with respect to the foregoing in all countries.

9. Remedies.

Employee acknowledges that
any material breach of this Agreement will cause irreparable harm to the Company, that such harm will be difficult if not impossible
to ascertain, and that the Company shall be entitled to equitable relief, including injunction, against any actual or threatened
breach hereof, without bond and without liability should such relief be denied, modified or vacated. Neither the right to
obtain such relief nor the obtaining of such relief shall be exclusive of or preclude the Company from any other
remedy.

10. Legal Counsel.

Employee acknowledges that
Employee has carefully read this Agreement and understands all of the terms hereof and that Employee has been given the opportunity to
discuss this Agreement with Employee's private legal counsel and has availed himself of that opportunity
to the extent Employee wishes to do so.

11. Notices.

All notices, requests and
other communications under this Agreement shall be in writing and shall be deemed to have been received five business days
after having been deposited in the United States Mail and enclosed in a registered or certified post-paid envelope; one day after
having been sent by overnight courier on a business day or otherwise at the open of business on the next
succeeding business day; when personally delivered or sent by facsimile communications equipment of the sending party
on a business day or otherwise at the open of business on the next succeeding business day; and, in each case, addressed
to the respective parties at the addresses stated below or to such other changed addresses that the parties may
have fixed by notice in accordance herewith.

If to the Company:

Zander Therapeutics, Inc.

4700 Sprint Street, Suite 304

La Mesa, CA 91942

 

Attn: David Koos, CEO

 

 

 

If to Employee:

Todd S Caven

toddcaven@saguarocapitalpartners.com

 

12. Waiver of Breach.

A waiver by the Company or Employee
of a breach of any provision of this Agreement by the other party shall not operate or be construed
as a waiver of any subsequent breach by the other party.

13. Entire Agreement.

	 	6	 

    	 

    	 

    

 

This instrument contains the
entire agreement of the parties with respect to the subject matter hereof and supersedes any prior agreements of
the parties with respect to the subject matter hereof. It may be changed only by an agreement in
writing signed by a party against whom enforcement of any waiver, change, modification, extension
or discharge is sought.

 14. Applicable Law.

 The terms and conditions
of this Agreement shall be governed by and construed in accordance with the laws of the State or
California. Any action to enforce this Agreement shall be brought in the state courts located in San Diego County, State
of California.

IN WHITNESS WHEREOF, the parties hereto have executed
this Agreement as of the day and year first above written.

By:/s/David Koos

________________________ 

David R. Koos

Chief Executive Officer

 

By: /s/Todd S. Caven

_________________________

Todd S. Caven

 

 

Schedule 1.

 Employer: Zander Therapeutics, Inc.

 

Location: Company
Headquarters and any remote offices Description:

Job Description - Chief
Financial Officer

 

Job Summary

 

The CFO, reporting
directly to the CEO, will develop a robust strategic plan and vision for the advancement of Zander's research into commercial products.
The CFOt leads the growth of Zander's technology, whether from in-house research or through corporate or academic partnerships,
business development, and commercialization initiatives to support Zander's vision.

 

 

 

He/she leads the development
of the commercial innovation capability at Zander to execute a quantifiable business development strategy to catalyze the development
of new products and services. Zander expects to become a regional leader in moving innovation and research into the commercial
marketplace and will look to the incumbent to play a leading role in realizing

	 	7	 

    	 

    	 

    

 

that goal. The President ensures that the
research programs of Zander align with that of its vision and plays an important role in external relations.

 

 

Key Accountabilities

	 	•	The Chief Financial Officer, in concert with the CEO, will develop a robust strategic plan and vision for the advancement of Zander's research into commercial markets. The Chief Financial Officer leads the growth of Zander's business development, financing and commercialization initiatives to support Zander's vision.

 

	 	•	The Chief Financial Officer will devise an implementation plan that articulates how Zander will achieve its strategic plan. This will likely include milestones, a catalyst calendar and a plan for financing business operations.

 

	 	8	 

    	 

    	 

    

 

	 	•	In conjunction with the CEO, the Chief Financial Officer will identify strategies to raise capital to fund the enterprise. A use of funds document will be created and converted to a 1 and 2 year budget.

 

	 	•	CFO leads the development of the commercial innovation capability at Zander to execute a quantifiable business development strategy to catalyze the development of new products and services. Zander expects to become a regional leader in moving innovation and research to the commercial marketplace and will look to the incumbent to play a leading role in realizing that goal.

 

 

	 	•	The CFO is responsible for developing and managing external business relationships with key financial industry partners (including investment banks, funds, private equity groups and institutional investors), leading commercialization partnerships and new ventures with industry.

 

	 	9	 

    	 

    	 

    

 

 

 

Schedule 2.

 

Vesting Schedule
for Milestone shares

 

	 	3.	Milestone Shares will be issued upon occurrence of any of the following events having occurred during the employment by the Company of the Employee. Milestone shares will vest immediately and are not subject to Transfer Restrictions.

 

a)
Two Million Milestone Shares will be issued upon the Chief Financial Officer raising$ 500,000 to finance the Company's operations.

b)
Two Million Milestone Shares will be issued upon the Chief Financial Officer raising a subsequent $500,000 to finance the
Company's operations.

c)
Two Million Milestone Shares will be issued upon the Chief Financial Officer raising a subsequent $500,000 to finance the
Company's operations.

d) Two
Million Milestone Shares will be issued upon the Chief Financial Officer raising a subsequent $500,000 to finance the Company's
operations.

e) Two
Million Milestone Shares will be issued upon the Chief Financial Officer raising a subsequent $500,000 to finance the Company's
operations.

 

To fully vest in the total 10 million milestone
shares, the Chief Financial Officer will have to raise $2 million for Zander Therapeutics in the tranches listed above in a) to
e).SECURITIES
PURCHASE AGREEMENT ZANDER THERAPEUTICS, INC.

 

THIS
SECURITIES PURCHASE AGREEMENT (the "Agreement") is entered into by and among Zander Therapeutics, Inc., a Nevada corporation
(the "Company") whose address is 4700 Spring Street, St 304, La Mesa, California 91942, and ______________("Purchaser
'), a trust whose address is____________________.

 

The
Securities offered have not been, and will not be, registered under the Securities Act of 1933, as amended (the "Act")
and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons except pursuant
to an exemption from, or in a transaction not subject to, the registration requirement of the Act. The Securities are being offered
and sold only to "accredited investors" (as defined in Rule 501 of Regulation D under the Securities Act).

 

WHEREAS:

The
Purchaser desires to purchase shares of the common stock of the Company ("Shares") in accordance with the terms and
conditions set forth herein.

The
Company desires to issue and sell Shares to the Purchaser in accordance with the terms and conditions set forth herein.

THEREFORE,
IT IS AGREED AS FOLLOWS

 1. Purchase Price

 

The
purchase price per Share ('"Purchase Price"), payable in US Dollars, shall be $2.00 per Share. 

 2. Form of Payment

 

The
Purchaser shall pay the Purchase Price per Share multiplied by that number of Shares Purchased by wire transfer of immediately
available funds to the Company.

WIRE
INSTRUCTIONS:

 

Zander
Therapeutics Wire Instructions:

 

 

    	 	1	 

     

    

Issuance of Stock

 

10
business days subsequent to receipt of payment of the Purchase Price the Company shall issue to the Purchaser that number of Shares
purchased

 3. Purchaser's Representations and Warranties

 

(a)  
As of the date hereof, the Purchaser
is purchasing the Shares for its own account and not with a present view towards the public sale or distribution thereof, except
pursuant to sales registered or exempted from registration under the Securities Act of 1933, as amended (the "Act").

 (b) The Purchaser is an '"accredited investor" as that term is defined in Rule 501(a) of Regulation D promulgated under the Act.

(c)  
The Purchaser and its advisors
if any, have been, furnished with all materials relating to the business, finances and operations of the Company and materials
relating to the offer and sale of the Stocks which have been requested by the Purchaser or its advisors. Notwithstanding the foregoing,
the Company has not disclosed to the Purchaser any material nonpublic information and will not disclose such information unless
such information is disclosed to the public prior to such disclosure to the Purchaser.

 (d) Purchaser has the requisite power and authority to enter into and perform its obligations under this Agreement without the consent, approval or authorization of, or obligation to notify, any person, entity or governmental agency which consent has not been obtained.

(e)  
The execution, delivery and performance
of this Agreement by Purchaser does not and shall not constitute Purchaser's breach of any statute or regulation or ordinance
of any governmental authority, and shall not conflict with or result in a breach of or default under any of the terms, conditions,
or provisions of any order, writ, injunction, decree, contract, agreement, or instrument to which the Purchaser is a party, or
by which Purchaser is or may be bound.

 4. Company's representations and warranties

(a)
Company is a corporation duly organized,
validly existing and in good standing under the laws of the state its incorporation and has the requisite corporate power and
authority to enter into and perform its obligations under this Agreement without the consent, approval or

    	 	2	 

     

    

 authorization
of, or obligation to notify, any person, entity or governmental agency which consent has not been obtained.

(b) 
The execution, delivery and performance
of this Agreement by Company does not and shall not constitute Company's breach of any statute or regulation or ordinance of any
governmental authority, and shall not conflict with or result in a breach of or default under any of the terms, conditions, or
provisions of any order, writ, injunction, decree, contract, agreement, or instrument to which the Company is a party, or by which
Company is or may be bound.

 5. Restricted Securities Acknowledgement

 

SHARES
TO BE ISSUED PURSUANT TO THIS AGREEMENT WILL NOT BE REGISTERED WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION PURSUANT TO THE
SECURITIES ACT OF 1933 OR THE SECURITIES LAW OF ANY STATE OR OTHER JURISDICTION.

Purchaser
acknowledges that any securities issued pursuant to this Agreement shall not be registered pursuant to the Securities Act of 1933
and shall constitute "restricted securities" as that term is defined in Rule 144 promulgated under the Act, and shall
contain the following restrictive legend:

"THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ''ACT"), OR SECURITIES LAWS OF ANY
STATE AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION
STATEMENT UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION UNDER THE
ACT OR SUCH LAWS AND, IF REQUESTED BY THE COMPANY, UPON DELIVERY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY
THAT THE PROPOSED TRANSFER IS EXEMPT FROM THE ACT OR SUCH LAWS."

 9. Entire Agreement

 

This
Agreement constitutes a final written expression of all the terms of the Agreement between the parties regarding the subject matter
hereof, are a complete and exclusive statement of those terms, and supersedes all prior and contemporaneous Agreements, understandings,
and representations between the parties.

 10. Governing Law, Venue, Waiver Of Jury Trial

 

All
questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed
and enforced in accordance with the internal laws of the State of California, without regard to the principles of conflicts of
law thereof. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in

    	 	3	 

     

    

 

California for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated
hereby or discussed herein and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim
that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or inconvenient
venue for such proceeding. If either party shall commence an action or proceeding to enforce
any provisions of this Agreement, then the prevailing party in such action or proceeding shall be reimbursed by the other party
for its attorneys' fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action
or proceeding.

 

 

IN
WITNESS WHEREOF, the parties have
hereunto executed this Agreement on the 15th day of June, 2018.

 

 

Zander
Therapeutics, Inc.

/s/David
Koos

David
Koos, CEO

Date:
June 16, 2018

  

Purchaser

_______________

Date:
June 15, 2018

 

Purchaser

 

Number
of shares of common Stock Purchased:50,000 shares

Total
Purchase Price: $2 Per Share

 

    	 	4	 

     

    

 

 

 

 SECURITIES
PURCHASE AGREEMENT ZANDER THERAPEUTICS, INC.

 

THIS
SECURITIES PURCHASE AGREEMENT (the "Agreement") is entered into by and among Zander Therapeutics, Inc., a Nevada corporation
(the "Company") whose address is 4700 Spring Street, St 304, La Mesa, California 91942, and Brian Devine, ITEE for the
Devine Family Trust ("Purchaser"), a person whose address is P.O. Box 1305, Rancho Santa Fe, CA. 92067.

The
Securities offered have not been, and will not be, registered under the Securities Act of 1933, as amended (the "Act")
and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons except pursuant
to an exemption from, or in a transaction not subject to, the registration requirement of the Act. The Securities are being offered
and sold only to "accredited investors" (as defined in Rule 501 of Regulation D under the Securities Act).

 

WHEREAS:

The
Purchaser desires to purchase shares of the common stock of the Company ("Shares") in accordance with the terms and
conditions set forth herein.

 

The
Company desires to issue and sell Shares to the Purchaser in accordance with the terms and conditions set forth herein.

 

THEREFORE,
IT IS AGREED AS FOLLOWS

 

1.
Purchase Price

The
purchase price per Share ("Purchase Price"), payable in US Dollars, shall be $1.00 per Share.

 2. Form of Payment

The
Purchaser shall pay the Purchase Price per Share multiplied by that number of Shares Purchased by wire transfer of immediately
available funds to the Company on or prior to August 17, 2018

WIRE
INSTRUCTIONS:

Zander
Therapeutics Wire Instructions:

 

__________________________

 

    	 	5	 

     

    

 

3.
Issuance of Stock

 

5
business days subsequent to receipt of payment of the Purchase Price the Company shall issue to the Purchaser that number of Shares
purchased

4.
Purchaser's Representations and Warranties

 

 (a) As of the date hereof, the Purchaser is purchasing the Shares for its own account and not with a present view towards the public sale or distribution thereof, except pursuant to sales registered or exempted from registration under the Securities Act of 1933, as amended (the ··Act").

 (b) The Purchaser is an ··accredited investor'' as that tennis defined in Rule 50l(a) of Regulation D promulgated under the Act

 (c) The Purchaser and its advisors, if any, have been, furnished with all materials relating to the business, finances and operations of the Company and materials relating to the offer and sale of the Stocks which have been requested by the Purchaser or its advisors. Notwithstanding the foregoing, the Company has not disclosed to the Purchaser any material nonpublic information and will not disclose such information unless such information is disclosed to the public prior to such disclosure to the Purchaser.

 (d) Purchaser has the requisite power and authority to enter into and perfonn its obligations under this Agreement without the consent, approval or authorization of, or obligation to notify, any person, entity or governmental agency which consent has not been obtained.

 (e) The execution, delivery and performance of this Agreement by Purchaser does not and shall not constitute Purchaser's breach of any statute or regulation or ordinance of any governmental authority, and shall not conflict with or result in a breach of or default under any of the terms, conditions, or provisions of any order, writ, injunction, decree, contract, agreement, or instrument to which the Purchaser is a party, or by which Purchaser is or may be bound.

 5. Company's representations and warranties

 

(a) 
Company is a corporation duly organized,
validly existing and in good standing under the laws of the state its incorporation and has the requisite corporate power and
authority to enter into and perform its obligations under this Agreement without the consent, approval or authorization of, or
obligation to notify, any person, entity or governmental agency which consent has not been obtained.

(b) 
The execution delivery and performance
of this Agreement by Company does not and shall not constitute Company’s breach of any statute or regulation or ordinance
of any

    	 	6	 

     

    

 

 

governmental
authority, and shall not conflict \\'1th or result in a breach of or default under any of the terms, conditions or provisions
of any order writ injunction decree, contract, agreement, or instrument to which the Company is a party, or by which Company is
or may be bound.

 6. Restricted Securities Acknowledgement

 

Purchaser
acknowledges that any securities issued pursuant to this Agreement that shall not be registered pursuant to the Securities Act
of 1933 shall constitute ·'restricted securities'' as that term is defined in Rule
144 promulgated under the Act, and shall contain the following restrictive legend:

 

"THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ··ACT'), OR
SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED.
TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND APPLICABLE STATE
SECURITIES LAWS OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION UNDER THE ACT OR SUCH LAWS AND, IF REQUESTED BY THE
COMPANY, UPON DELIVERY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT THE PROPOSED TRANSFER IS EXEMPT
FROM THE ACT OR SUCH LAWS”

 

 9. Entire Agreement

 

This
Agreement constitutes a final written expression of all the terms of the Agreement between the parties regarding the subject matter
hereof, are a complete and exclusive statement of those terms, and supersedes all prior and contemporaneous Agreements, understandings,
and representations between the parties.

 

 10. Governing Law, Venue, Waiver Of Jury Trial

 

All
questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed
and enforced in accordance with the internal laws of the State of California, without regard to the principles of conflicts of
law thereof. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in California
for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed
herein and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court that such suit, action or proceeding is improper
or inconvenient venue for such proceeding. If either party shall commence an action or
proceeding to enforce any provisions of this Agreement, then the prevailing party in such action or proceeding shall be reimbursed
by the other party for its attorneys' fees and other costs and expenses incurred with the investigation, preparation and prosecution
of such action or proceeding.

 

    	 	7	 

     

    

 

IN
WITNESS WHEREOF the parties have
hereunto executed this Agreement 

 

 

 

Zander
Therapeutics, Inc.

/s/David
Koos 

David
Koos CEO

Date: 08/14/2018

 

Purchaser

 

/s/Brian Devine

By:
Brian Devine

TTEE F/O/B

The Devine Family Trust

Date:
August 11 2018

 

Number
of shares of common Stock

Purchased: 300,000 shares Total Purchase Price: $300, 000

 

 

    	 	8	 

     

    

 

SECURITIES
PURCHASE AGREEMENT ZANDER THERAPEUTICS, INC.

 

THIS
SECURITIES PURCHASE AGREEMENT (the "Agreement") is entered into by and among Zander Therapeutics, Inc., a Nevada corporation
(the "Company") whose address is 4700 Spring Street, St 304, La Mesa, California 91942, and BRIAN DEVINE TTEE for the
Brian Devine Jr. Irrevocable Trust ("Purchaser '), a trust whose address is PO Box 1305 Rancho Santa Fe CA 92067.

 

The
Securities offered have not been, and will not be, registered under the Securities Act of 1933, as amended (the "Act")
and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons except pursuant
to an exemption from, or in a transaction not subject to, the registration requirement of the Act. The Securities are being offered
and sold only to "accredited investors" (as defined in Rule 501 of Regulation D under the Securities Act).

 

WHEREAS:

 

The
Purchaser desires to purchase shares of the common stock of the Company ("Shares") in accordance with the terms and
conditions set forth herein.

 

The
Company desires to issue and sell Shares to the Purchaser in accordance with the terms and conditions set forth herein.

 

THEREFORE,
IT IS AGREED AS FOLLOWS

 

 6. Purchase Price

 

The
purchase price per Share ('"Purchase Price"), payable in US Dollars, shall be $2.00 per Share.

 

 7. Form of Payment

 

The
Purchaser shall pay the Purchase Price per Share multiplied by that number of Shares Purchased by wire transfer of immediately
available funds to the Company.

WIRE
INSTRUCTIONS:

 

Zander
Therapeutics Wire Instructions:

 

 

    	 	9	 

     

    

Issuance
of Stock

 

10
business days subsequent to receipt of payment of the Purchase Price the Company shall issue to the Purchaser that number of Shares
purchased

 

8.
Purchaser's Representations and Warranties

 

(f)   
As of the date hereof, the Purchaser
is purchasing the Shares for its own account and not with a present view towards the public sale or distribution thereof, except
pursuant to sales registered or exempted from registration under the Securities Act of 1933, as amended (the "Act").

 

 (g) The Purchaser is an '"accredited investor" as that term is defined in Rule 501(a) of Regulation D promulgated under the Act.

 

(h)  
The Purchaser and its advisors
if any, have been, furnished with all materials relating to the business, finances and operations of the Company and materials
relating to the offer and sale of the Stocks which have been requested by the Purchaser or its advisors. Notwithstanding the foregoing,
the Company has not disclosed to the Purchaser any material nonpublic information and will not disclose such information unless
such information is disclosed to the public prior to such disclosure to the Purchaser.

 

 (i) Purchaser has the requisite power and authority to enter into and perform its obligations under this Agreement without the consent, approval or authorization of, or obligation to notify, any person, entity or governmental agency which consent has not been obtained.

 

(j)   
The execution, delivery and performance
of this Agreement by Purchaser does not and shall not constitute Purchaser's breach of any statute or regulation or ordinance
of any governmental authority, and shall not conflict with or result in a breach of or default under any of the terms, conditions,
or provisions of any order, writ, injunction, decree, contract, agreement, or instrument to which the Purchaser is a party, or
by which Purchaser is or may be bound.

 

9.
Company's representations and warranties

 

 (c) Company is a corporation duly organized, validly existing and in good standing under the laws of the state its incorporation and has the requisite corporate power and authority to enter into and perform its obligations under this Agreement without the consent, approval or

    	 	10	 

     

    

authorization of, or obligation to notify, any person, entity or governmental agency which consent has not been obtained.

 

(d) 
The execution, delivery and performance
of this Agreement by Company does not and shall not constitute Company's breach of any statute or regulation or ordinance of any
governmental authority, and shall not conflict with or result in a breach of or default under any of the terms, conditions, or
provisions of any order, writ, injunction, decree, contract, agreement, or instrument to which the Company is a party, or by which
Company is or may be bound.

 

 10. Restricted Securities Acknowledgement

 

SHARES
TO BE ISSUED PURSUANT TO THIS AGREEMENT WILL NOT BE REGISTERED WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION PURSUANT TO THE
SECURITIES ACT OF 1933 OR THE SECURITIES LAW OF ANY STATE OR OTHER JURISDICTION.

 

Purchaser
acknowledges that any securities issued pursuant to this Agreement shall not be registered pursuant to the Securities Act of 1933
and shall constitute "restricted securities" as that term is defined in Rule 144 promulgated under the Act, and shall
contain the following restrictive legend:

 

"THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ''ACT"), OR SECURITIES LAWS OF ANY
STATE AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION
STATEMENT UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION UNDER THE
ACT OR SUCH LAWS AND, IF REQUESTED BY THE COMPANY, UPON DELIVERY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY
THAT THE PROPOSED TRANSFER IS EXEMPT FROM THE ACT OR SUCH LAWS."

 

 11. Entire Agreement

 

This
Agreement constitutes a final written expression of all the terms of the Agreement between the parties regarding the subject matter
hereof, are a complete and exclusive statement of those terms, and supersedes all prior and contemporaneous Agreements, understandings,
and representations between the parties.

 

 12. Governing Law, Venue, Waiver Of Jury Trial

 

All
questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed
and enforced in accordance with the internal laws of the State of California, without regard to the principles of conflicts of
law thereof. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in

 

    	 	11	 

     

    

 

California for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated
hereby or discussed herein and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim
that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or inconvenient
venue for such proceeding. If either party shall commence an action or proceeding to enforce
any provisions of this Agreement, then the prevailing party in such action or proceeding shall be reimbursed by the other party
for its attorneys' fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action
or proceeding.

 

 

 

 

IN
WITNESS WHEREOF, the parties have
hereunto executed this Agreement

 

 

Zander
Therapeutics, Inc.

/s/David
Koos

David
Koos, CEO

Date:
August 14, 2018

 

 

Purchaser

/s/Brian
Devine

 

Brian
Devine TTEE/FOB

The
Brian Devine Jr. Irrevocable Trust

Date:
August 11, 2018

 

Purchaser

 

Number
of shares of common Stock Purchased:100,000 shares

 

Total
Purchase Price: $100,000

 

 

    	 	12	 

     

    

SECURITIES
PURCHASE AGREEMENT ZANDER THERAPEUTICS, INC.

 

THIS
SECURITIES PURCHASE AGREEMENT (the "Agreement") is entered into by and among Zander Therapeutics, Inc., a Nevada corporation
(the "Company") whose address is 4700 Spring Street, St 304, La Mesa, California 91942, and BRIAN DEVINE TTEE for the
Devine Descendants Irrevocable Trust ("Purchaser '), a trust whose address is PO Box 1305 Rancho Santa Fe CA 92067.

 

The
Securities offered have not been, and will not be, registered under the Securities Act of 1933, as amended (the "Act")
and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons except pursuant
to an exemption from, or in a transaction not subject to, the registration requirement of the Act. The Securities are being offered
and sold only to "accredited investors" (as defined in Rule 501 of Regulation D under the Securities Act).

 

WHEREAS:

 

The
Purchaser desires to purchase shares of the common stock of the Company ("Shares") in accordance with the terms and
conditions set forth herein.

 

The
Company desires to issue and sell Shares to the Purchaser in accordance with the terms and conditions set forth herein.

 

THEREFORE,
IT IS AGREED AS FOLLOWS

 

 11. Purchase Price

 

The
purchase price per Share ('"Purchase Price"), payable in US Dollars, shall be $2.00 per Share.

 

 12. Form of Payment

 

The
Purchaser shall pay the Purchase Price per Share multiplied by that number of Shares Purchased by wire transfer of immediately
available funds to the Company.

 

WIRE
INSTRUCTIONS:

 

Zander
Therapeutics Wire Instructions:

 

    	 	13	 

     

    

 

Issuance of Stock

 

10
business days subsequent to receipt of payment of the Purchase Price the Company shall issue to the Purchaser that number of Shares
purchased

 

13.
Purchaser's Representations and Warranties

 

(k)  
As of the date hereof, the Purchaser
is purchasing the Shares for its own account and not with a present view towards the public sale or distribution thereof, except
pursuant to sales registered or exempted from registration under the Securities Act of 1933, as amended (the "Act").

 

 (l) The Purchaser is an '"accredited investor" as that term is defined in Rule 501(a) of Regulation D promulgated under the Act.

 

(m)
The Purchaser and its advisors
if any, have been, furnished with all materials relating to the business, finances and operations of the Company and materials
relating to the offer and sale of the Stocks which have been requested by the Purchaser or its advisors. Notwithstanding the foregoing,
the Company has not disclosed to the Purchaser any material nonpublic information and will not disclose such information unless
such information is disclosed to the public prior to such disclosure to the Purchaser.

 

 (n) Purchaser has the requisite power and authority to enter into and perform its obligations under this Agreement without the consent, approval or authorization of, or obligation to notify, any person, entity or governmental agency which consent has not been obtained.

 

(o)  
The execution, delivery and performance
of this Agreement by Purchaser does not and shall not constitute Purchaser's breach of any statute or regulation or ordinance
of any governmental authority, and shall not conflict with or result in a breach of or default under any of the terms, conditions,
or provisions of any order, writ, injunction, decree, contract, agreement, or instrument to which the Purchaser is a party, or
by which Purchaser is or may be bound.

 

14.
Company's representations and warranties

 

(e)
Company is a corporation duly organized,
validly existing and in good standing under the laws of the state its incorporation and has the requisite corporate power and
authority to enter into and perform its obligations under this Agreement without the consent, approval or

    	 	14	 

     

    

authorization
of, or obligation to notify, any person, entity or governmental agency which consent has not been obtained.

 

(f)  
The execution, delivery and performance
of this Agreement by Company does not and shall not constitute Company's breach of any statute or regulation or ordinance of any
governmental authority, and shall not conflict with or result in a breach of or default under any of the terms, conditions, or
provisions of any order, writ, injunction, decree, contract, agreement, or instrument to which the Company is a party, or by which
Company is or may be bound.

 

 15. Restricted Securities Acknowledgement

 

SHARES
TO BE ISSUED PURSUANT TO THIS AGREEMENT WILL NOT BE REGISTERED WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION PURSUANT TO THE
SECURITIES ACT OF 1933 OR THE SECURITIES LAW OF ANY STATE OR OTHER JURISDICTION.

 

Purchaser
acknowledges that any securities issued pursuant to this Agreement shall not be registered pursuant to the Securities Act of 1933
and shall constitute "restricted securities" as that term is defined in Rule 144 promulgated under the Act, and shall
contain the following restrictive legend:

 

"THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ''ACT"), OR SECURITIES LAWS OF ANY
STATE AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION
STATEMENT UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION UNDER THE
ACT OR SUCH LAWS AND, IF REQUESTED BY THE COMPANY, UPON DELIVERY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY
THAT THE PROPOSED TRANSFER IS EXEMPT FROM THE ACT OR SUCH LAWS."

 

 13. Entire Agreement

 

This
Agreement constitutes a final written expression of all the terms of the Agreement between the parties regarding the subject matter
hereof, are a complete and exclusive statement of those terms, and supersedes all prior and contemporaneous Agreements, understandings,
and representations between the parties.

 

 14. Governing Law, Venue, Waiver Of Jury Trial

 

All
questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed
and enforced in accordance with the internal laws of the State of California, without regard to the principles of conflicts of
law thereof. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in

 

    	 	15	 

     

    

 

California for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated
hereby or discussed herein and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim
that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or inconvenient
venue for such proceeding. If either party shall commence an action or proceeding to enforce
any provisions of this Agreement, then the prevailing party in such action or proceeding shall be reimbursed by the other party
for its attorneys' fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action
or proceeding.

 

 

 

IN
WITNESS WHEREOF, the parties have
hereunto executed this Agreement

 

 

Zander
Therapeutics, Inc.

/s/David
Koos

David
Koos, CEO

Date:
August 14, 2018

 

 

Purchaser

/s/Brian
Devine

 

Brian
Devine TTEE/FOB

The
Devine Descendants Irrevocable Trust

Date:
August 11, 2018

 

Purchaser

 

Number
of shares of common Stock Purchased: 100,000 shares

Total
Purchase Price: $100,000

 

    	 	16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}]]